C10orf30 Inhibitors
Chemical inhibitors of C10orf30 target various signaling pathways and cellular processes to achieve functional inhibition of the protein's activity. Palbociclib, by selectively inhibiting cyclin-dependent kinases CDK4 and CDK6, can impede cell cycle progression, which is essential for the proper functioning of C10orf30 if it is associated with cell cycle regulation. Staurosporine, with its broad protein kinase inhibition profile, can disrupt phosphorylation-dependent pathways that C10orf30 may be a part of, effectively inhibiting the protein's activity. LY294002 and Wortmannin, both phosphoinositide 3-kinase (PI3K) inhibitors, can hinder the PI3K/Akt pathway, potentially leading to functional inhibition of C10orf30 if it is involved in this signaling cascade.
Furthermore, Rapamycin, by inhibiting mTOR signaling, can affect the activity of C10orf30 if the protein's function is linked to mTOR-regulated pathways. SB203580 and PD98059 target the p38 MAP kinase and MEK1/2, respectively; the inhibition of these kinases can suppress essential signaling routes that C10orf30 may utilize, leading to its functional inhibition. MG132's role as a proteasome inhibitor can lead to the accumulation and subsequent functional inhibition of C10orf30 if its activity is regulated through proteasomal degradation. SP600125 and PP2, by inhibiting c-Jun N-terminal kinase (JNK) and Src family tyrosine kinases respectively, can interfere with signaling pathways that C10orf30 requires for its function. Lastly, Y-27632, as a ROCK inhibitor, can inhibit the Rho/ROCK pathway, which can be crucial for the functional activity of C10orf30 within cellular signaling networks. Each chemical provides a unique mechanism by which to inhibit the activity of C10orf30 by targeting specific pathways and processes that are essential for its role in the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. C10orf30 may be involved in cell cycle regulation; inhibition of CDK4/6 by Palbociclib could impede cell cycle progression, potentially leading to functional inhibition of C10orf30 by preventing its associated cellular processes. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. C10orf30, if involved in phosphorylation-dependent pathways, would be functionally inhibited by Staurosporine's broad kinase inhibition, which could disrupt signaling pathways necessary for C10orf30's activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinase (PI3K) inhibitor. PI3K signaling is integral to many cellular processes; inhibition by LY294002 could lead to downstream effects that functionally inhibit C10orf30 if it is part of the PI3K pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor and could functionally inhibit C10orf30 by inhibiting mTOR signaling pathways that are crucial for many cellular functions, potentially including those associated with C10orf30 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase. If C10orf30 operates within the p38 MAPK pathway, inhibition by SB203580 would suppress the pathway's activity, leading to functional inhibition of C10orf30. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2. C10orf30, if involved in the ERK/MAPK pathway, would be functionally inhibited through the blockade of this signaling route by U0126, preventing necessary phosphorylation events. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that can functionally inhibit C10orf30 by curtailing the PI3K/Akt pathway, which may be essential for C10orf30's role in cellular processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a specific inhibitor of MEK, which would lead to functional inhibition of C10orf30 if it is reliant on the MEK/ERK pathway for its activity within the cell. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor. If C10orf30 is regulated through proteasomal degradation, inhibition by MG132 could cause functional inhibition through the accumulation of C10orf30, potentially disrupting its normal activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). If C10orf30's function is modulated by JNK signaling, inhibition by SP600125 would lead to functional inhibition of C10orf30 through this pathway. | ||||||